Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics Inc (NQ: ELTX )

9.130 +0.030 (+0.33%)
Streaming Delayed Price Updated: 11:51 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,544
Open 9.150
Bid (Size) 9.100 (1)
Ask (Size) 9.150 (26)
Prev. Close 9.100
Today's Range 8.858 - 9.150
52wk Range 2.960 - 24.39
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry 
Via News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
+53.96%
+53.96%
1 Month
+28.23%
+28.23%
3 Month
+96.34%
+96.34%
6 Month
+39.50%
+39.50%
1 Year
-49.68%
-49.68%

More News

Read More
Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform
Via News Direct
Topics Death
Exposures Death
ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
Via Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P
Via News Direct
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
Via News Direct
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
Via Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P
Via Benzinga
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
Via News Direct
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.